Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jan;79(2):286–292. doi: 10.1038/sj.bjc.6690046

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines

P Engblom 1,2, V Rantanen 1,2, J Kulmala 3, H Helenius 4, S Grènman 1,2
PMCID: PMC2362186  PMID: 9888470

Abstract

The purpose of this study was to compare the growth-inhibitory effect of cisplatin–paclitaxel with that obtained with a cisplatin–docetaxel combination and to assess the type of interaction. Concomitant use of taxanes and cisplatin was studied in seven human ovarian carcinoma cell lines, using the 96-well plate clonogenic assay. Chemosensitivity was expressed in terms of IC50 values, the drug concentration causing 50% inhibition of clonogenic survival. The type of interaction was studied using the area under the survival curve ratios (AUC ratios) obtained by numerical integration. Comparison of the AUC ratio and the surviving fraction (SF) value after taxane alone was made using Student's t-test. The influence of the drug concentration was tested by one-way analysis of variance (Anova). A supra-additive or additive effect was seen when seven ovarian carcinoma cell lines were exposed to paclitaxel or docetaxel concomitantly with cisplatin. A supra-additive effect was found in four cell lines (UT-OC-3, UT-OC-4, UT-OC-5 and SK-OV-3) after simultaneous use of cisplatin with all docetaxel concentrations tested, and in two cell lines (UT-OC-4 and SK-OV-3) when cisplatin was used concomitantly with paclitaxel. A more pronounced supra-additive effect was seen with the combination of cisplatin and docetaxel. The degree of supra-additivity was dose dependent, with increasing synergy after a higher taxane dose. The data obtained in this study suggest that a supra-additive or additive effect can be achieved in ovarian carcinoma with the concomitant use of cisplatin and a taxane. © 1999 Cancer Research Campaign

Keywords: taxanes, cisplatin, interaction, chemosensitivity, ovarian carcinoma

Full Text

The Full Text of this article is available as a PDF (98.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arbuck S. G., Canetta R., Onetto N., Christian M. C. Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol. 1993 Aug;20(4 Suppl 3):31–39. [PubMed] [Google Scholar]
  2. Burris H. A., 3rd, Fields S., Peacock N. Docetaxel (Taxotere) in combination: a step forward. Semin Oncol. 1995 Dec;22(6 Suppl 13):35–40. [PubMed] [Google Scholar]
  3. Chou T. C., Otter G. M., Sirotnak F. M. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol. 1996;37(3):222–228. doi: 10.1007/BF00688320. [DOI] [PubMed] [Google Scholar]
  4. Díaz J. F., Andreu J. M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 1993 Mar 23;32(11):2747–2755. doi: 10.1021/bi00062a003. [DOI] [PubMed] [Google Scholar]
  5. Engblom P., Rantanen V., Kulmala J., Grènman S. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay. Anticancer Res. 1996 Jul-Aug;16(4A):1743–1747. [PubMed] [Google Scholar]
  6. Engblom P., Rantanen V., Kulmala J., Heiskanen J., Grenman S. Taxane sensitivity of ovarian carcinoma in vitro. Anticancer Res. 1997 Jul-Aug;17(4A):2475–2479. [PubMed] [Google Scholar]
  7. Fogh J., Wright W. C., Loveless J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977 Feb;58(2):209–214. doi: 10.1093/jnci/58.2.209. [DOI] [PubMed] [Google Scholar]
  8. Grenman R., Burk D., Virolainen E., Buick R. N., Church J., Schwartz D. R., Carey T. E. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer. 1989 Jul 15;44(1):131–136. doi: 10.1002/ijc.2910440123. [DOI] [PubMed] [Google Scholar]
  9. Gullo J. J., Litterst C. L., Maguire P. J., Sikic B. I., Hoth D. F., Woolley P. V. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol. 1980;5(1):21–26. doi: 10.1007/BF00578558. [DOI] [PubMed] [Google Scholar]
  10. Guéritte-Voegelein F., Guénard D., Lavelle F., Le Goff M. T., Mangatal L., Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991 Mar;34(3):992–998. doi: 10.1021/jm00107a017. [DOI] [PubMed] [Google Scholar]
  11. Hill B. T., Whelan R. D., Shellard S. A., McClean S., Hosking L. K. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs. 1994;12(3):169–182. doi: 10.1007/BF00873957. [DOI] [PubMed] [Google Scholar]
  12. Huizing M. T., Keung A. C., Rosing H., van der Kuij V., ten Bokkel Huinink W. W., Mandjes I. M., Dubbelman A. C., Pinedo H. M., Beijnen J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993 Nov;11(11):2127–2135. doi: 10.1200/JCO.1993.11.11.2127. [DOI] [PubMed] [Google Scholar]
  13. Jekunen A. P., Christen R. D., Shalinsky D. R., Howell S. B. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer. 1994 Feb;69(2):299–306. doi: 10.1038/bjc.1994.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kelland L. R., Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol. 1992;30(6):444–450. doi: 10.1007/BF00685595. [DOI] [PubMed] [Google Scholar]
  15. Koechli O. R., Sevin B. U., Perras J. P., Chou T. C., Angioli R., Steren A., Untch M., Averette H. E. Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res Treat. 1993 Oct;28(1):21–27. doi: 10.1007/BF00666352. [DOI] [PubMed] [Google Scholar]
  16. Lavelle F., Bissery M. C., Combeau C., Riou J. F., Vrignaud P., André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995 Apr;22(2 Suppl 4):3–16. [PubMed] [Google Scholar]
  17. Lopes N. M., Adams E. G., Pitts T. W., Bhuyan B. K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol. 1993;32(3):235–242. doi: 10.1007/BF00685842. [DOI] [PubMed] [Google Scholar]
  18. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. doi: 10.1056/NEJM199601043340101. [DOI] [PubMed] [Google Scholar]
  19. Rantanen V., Grénman S., Kulmala J., Grénman R. Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. Br J Cancer. 1994 Mar;69(3):482–486. doi: 10.1038/bjc.1994.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Riou J. F., Naudin A., Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun. 1992 Aug 31;187(1):164–170. doi: 10.1016/s0006-291x(05)81474-3. [DOI] [PubMed] [Google Scholar]
  21. Rowinsky E. K., Donehower R. C., Jones R. J., Tucker R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 1988 Jul 15;48(14):4093–4100. [PubMed] [Google Scholar]
  22. Thigpen J. T., Blessing J. A., Vance R. B., Lambuth B. W. Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol. 1989 Aug;16(4 Suppl 6):58–65. [PubMed] [Google Scholar]
  23. Untch M., Sevin B. U., Perras J. P., Angioli R., Untch A., Hightower R. D., Koechli O., Averette H. E. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol. 1994 Apr;53(1):44–49. doi: 10.1006/gyno.1994.1085. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES